Cargando…

Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders

Detalles Bibliográficos
Autores principales:	Isenberg, David A., Kao, Amy H., Aydemir, Aida, Merrill, Joan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687657/ https://www.ncbi.nlm.nih.gov/pubmed/33262771 http://dx.doi.org/10.3389/fimmu.2020.592639

Ejemplares similares

Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
por: Kaegi, Celine, et al.
Publicado: (2020)

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty‐Four–Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Arm, Phase IIb Study
por: Merrill, Joan T., et al.
Publicado: (2018)

Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies
por: Studham, Matthew, et al.
Publicado: (2023)

Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme
por: Gordon, Caroline, et al.
Publicado: (2019)

Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study
por: Morand, Eric F, et al.
Publicado: (2020)

Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria
por: Barratt, Jonathan, et al.
Publicado: (2022)

Kinetics of free and ligand-bound atacicept in human serum
por: Eslami, Mahya, et al.
Publicado: (2022)

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus
por: Cogollo, Estafania, et al.
Publicado: (2015)

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
por: Kaegi, Celine, et al.
Publicado: (2019)

Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders
por: Arnold, Dennis D., et al.
Publicado: (2022)

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
por: Isenberg, David, et al.
Publicado: (2015)

Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders
por: Kaegi, Celine, et al.
Publicado: (2022)

Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
por: Isenberg, David, et al.
Publicado: (2014)

Site-specific N- and O-glycosylation analysis of atacicept
por: Stavenhagen, Kathrin, et al.
Publicado: (2019)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
por: Willen, Daniela, et al.
Publicado: (2019)

Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Wang, Si-Hang, et al.
Publicado: (2021)

Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016)

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus [Corrigendum]
Publicado: (2015)

No interactions between heparin and atacicept, an antagonist of B cell survival cytokines
por: Kowalczyk‐Quintas, Christine, et al.
Publicado: (2019)

Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials
por: Pitsiu, Maria, et al.
Publicado: (2023)

An Exploratory Dose-Escalating Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Atacicept in Patients with Systemic Lupus Erythematosus
por: Pena-Rossi, C, et al.
Publicado: (2009)

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial
por: van Vollenhoven, R. F., et al.
Publicado: (2015)

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
por: Ginzler, Ellen M, et al.
Publicado: (2012)

CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS
por: Kumar, Gaurav, et al.
Publicado: (2021)

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
por: Xiao, Hai, et al.
Publicado: (2021)

Commentary: Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis
por: Zeng, Boning, et al.
Publicado: (2020)

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
por: Rossi, J-F, et al.
Publicado: (2009)

Commentary on: “A common origin for immunity and digestion”
por: van Niekerk, Gustav, et al.
Publicado: (2015)

Commentary: Blurring Borders: Innate Immunity with Adaptive Features
por: Cooper, Edwin L.
Publicado: (2016)

Commentary: CD6 As a Potential Target for Treating Multiple Sclerosis
por: Consuegra-Fernández, Marta, et al.
Publicado: (2017)

Commentary: A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
por: Vaupel, Peter, et al.
Publicado: (2016)

Commentary: Is the developmentally immature immune response in paediatric sepsis a recapitulation of immune tolerance?
por: Muthukuru, Manoj
Publicado: (2019)

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis
por: Noori, Maryam, et al.
Publicado: (2023)

Editorial: Ankylosing Spondylitis and Related Immune-Mediated Disorders
por: Fiorillo, Maria Teresa, et al.
Publicado: (2019)

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab
por: Dey, Agnish, et al.
Publicado: (2022)

Commentary: Spatiotemporal Modeling of the Key Migratory Events During the Initiation of Adaptive Immunity
por: Mayer, Johannes U.
Publicado: (2019)

Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort
por: Desai, Ankit K., et al.
Publicado: (2020)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Commentary: PIRs Mediate Innate Myeloid Cell Memory to Nonself MHC Molecules
por: Cai, Zhenlong, et al.
Publicado: (2021)

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lsjarb03gaf3uh355n0o3ad4t2